Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Shilpa MedicareNSE:SHILPAMED -2.76%76 Pretax Margin % is 27.56% as of Mar. 2026, which is 47% above its 10-year median of 18.73. GuruFocus rates NSE:SHILPAMED with a GF Score™ of 76/100 and a GF Value™ of ₹387.78 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 961 Drug Manufacturers companies, Shilpa Medicare ranks better than 79.5% on this metric.
The historical rank and industry rank for Shilpa Medicare's Pretax Margin % or its related term are showing as below:
NSE:SHILPAMED'
s Pretax Margin % Range Over the Past 10 Years
Min: -3.67 Med: 18.73 Max: 21.67
Current: 19.2
NSE:SHILPAMED's Pretax Margin % is ranked better than 79.5% of 961
companies
in the Drug Manufacturers industry
Industry Median: 7.28
vs NSE:SHILPAMED: 19.20
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
Shilpa Medicare Pretax Margin % Related Terms
Shilpa Medicare Pretax Margin % Historical Data
* Premium members only.
The historical data trend for Shilpa Medicare's Pretax Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:SHILPAMED vs ZTS, UTHR: Pretax Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Shilpa Medicare's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shilpa Medicare Pretax Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Shilpa Medicare's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where Shilpa Medicare's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shilpa Medicare (NSE:SHILPAMED) has a Pretax Margin % of 27.56% as of Mar. 2026. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Shilpa Medicare and its competitors. This is 47% above median its historical median of 18.73. According to the industry distribution chart, Shilpa Medicare ranks #197 out of 961 companies in the Drug Manufacturers industry, placing it in the top 20.5%.
Is Shilpa Medicare's Pretax Margin % too high?
Shilpa Medicare's current Pretax Margin % of 27.56% is 47% above median its 10-year median of 18.73. The Drug Manufacturers industry median Pretax Margin % is 7.28. Shilpa Medicare's value of 27.56% is 278.6% above this industry median. Based on the distribution chart, Shilpa Medicare ranks #197 out of 961 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Shilpa Medicare has a GF Score™ of 76/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Shilpa Medicare's Pretax Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Shilpa Medicare ranks #197 out of 961 companies for Pretax Margin %. This places Shilpa Medicare in the top 21% of its industry — outperforming the majority of peers. The industry median Pretax Margin % is 7.28. Shilpa Medicare's value of 27.56% is 278.6% above this benchmark. While the company's 10-year median is 18.73 vs. the industry median of 7.28, Shilpa Medicare has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Drug Manufacturers company?
The median Pretax Margin % among Drug Manufacturers companies is 7.28, based on 961 companies in the industry. Companies in the top quartile (top 25%) have a Pretax Margin % significantly above this median, while those in the bottom quartile fall well below. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Shilpa Medicare's current Pretax Margin % of 27.56% is 278.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Shilpa Medicare and its competitors. For the Drug Manufacturers industry, the median Pretax Margin % is 7.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shilpa Medicare's current Pretax Margin % is 27.56%, which is 47% above median its own 10-year median of 18.73. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shilpa Medicare stock overvalued right now?
Based on GuruFocus' analysis, Shilpa Medicare (NSE:SHILPAMED) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹387.78, compared to a current price of ₹620.25 — trading 59.9% above its estimated fair value. The current Pretax Margin % is 27.56%, which is 47% above median its 10-year median of 18.73 and 278.6% above the Drug Manufacturers industry median of 7.28. Shilpa Medicare's overall GF Score™ is 76/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Shilpa Medicare (NSE:SHILPAMED), the current Pretax Margin % is 27.56% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shilpa Medicare (NSE:SHILPAMED) Overvalued in 2026?
Based on GuruFocus' analysis, Shilpa Medicare stock appears to be overvalued.
The current stock price of ₹620.25 is trading 59.9% above its estimated GF Value™ of ₹387.78.
GuruFocus considers Shilpa Medicare to be Significantly Overvalued.
Key valuation signals for NSE:SHILPAMED:
Pretax Margin %: 27.56% (47% above median its 10-year median of 18.73)
GF Value™: ₹387.78 vs. price of ₹620.25 (59.9% above fair value)
Industry Position: 278.6% above the Drug Manufacturers median (#197 of 961)
No single metric tells the full story. See the NSE:SHILPAMED stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shilpa Medicare Ltd is a specialty and generic drug manufacturer. The company deals in high-quality Active Pharmaceutical Ingredients (APIs), Intermediates, Formulations, New Drug Delivery Systems, Peptides, Biotech products, and Specialty Chemicals etc. Its portfolio comprises various oncology and non-oncology-related APIs such as anastrozole, acebrophylline, busulphan, decitabine, etc, and finished dosage formulations such as apremilast tablets, clofarabine injection, docetaxel injection, etc., in various therapy areas. Its reporting segments are: Pharmaceutical product and services, which derive maximum revenue, Power sales, and Others. Geographically, the company generates maximum revenue from India, followed by Europe, the United States of America, and the Rest of the world.
76GF Score
Get the complete analysis for NSE:SHILPAMED
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:SHILPAMED has been successfully added to your 
